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Regulation of cell proliferation and motility is essential for normal development. The Rho family of GTPases plays a critical role in the
control of cell polarity and migration by effecting the cytoskeleton, membrane trafficking, and cell adhesion. We investigated a recog-
nized developmental disorder, Adams-Oliver syndrome (AOS), characterized by the combination of aplasia cutis congenita (ACC)
and terminal transverse limb defects (TTLD). Through a genome-wide linkage analysis, we detected a locus for autosomal-dominant
ACC-TTLD on 3q generating a maximum LOD score of 4.93 at marker rs1464311. Candidate-gene- and exome-based sequencing led
to the identification of independent premature truncating mutations in the terminal exon of the Rho GTPase-activating protein 31
gene,ARHGAP31, which encodes a Cdc42/Rac1 regulatory protein.Mutant transcripts are stable and increase ARHGAP31 activity in vitro
through a gain-of-function mechanism. Constitutively active ARHGAP31 mutations result in a loss of available active Cdc42 and
consequently disrupt actin cytoskeletal structures. Arhgap31 expression in the mouse is substantially restricted to the terminal limb
buds and craniofacial processes during early development; these locations closely mirror the sites of impaired organogenesis that
characterize this syndrome. These data identify the requirement for regulated Cdc42 and/or Rac1 signaling processes during early
human development.Introduction
Members of the large family of GTPases act as molecular
switches that control many aspects of cell activity through
a remarkably simple biochemical mechanism of cycling
between two conformational forms. The active state
requires bound guanosine triphosphate (GTP) to allow
interaction with one of many effector proteins, whereas
the GTPase-mediated hydrolysis of GTP to guanosine
diphosphate (GDP) engenders an inactive state.1 Although
the Rho switch appears straightforward, the process is
closely controlled by at least three classes of regulators,
namely guanine nucleotide exchange factors (GEFs),
GTPase-activating proteins (GAPs) and GDP dissociation
inhibitors (GDIs). The Rho GTPases, which include
Cdc42 and Rac1, hold central functions in cell division,
survival, and migration; alterations in expression have
been widely studied in cancer and indicate a role in tumor
invasion and metastasis.2 However, regulation of cell
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stages. We have studied an inherited disorder characterized
by abnormalities of limb development, a recognized para-
digm of human organogenesis, and report a GAP regula-
tory defect as the primary cause.
Adams-Oliver syndrome (AOS; MIM 100300) describes
the congenital absence of skin, aplasia cutis congenita
(ACC), in combination with terminal transverse limb
defects (TTLD) (Figure 1A). Limb abnormalities typically
affect the distal phalanges or entire digits or, rarely, more
proximal limb structures. Important associated anomalies
include vascular cutis marmorata and cardiac and vascular
abnormalities, for example pulmonary hypertension.3
Although the combination of ACC and TTLD most often
occurs in sporadic cases, segregation within families is
consistent with autosomal-dominant inheritance in some
kindred and autosomal-recessive inheritance in others.
Variability of the disease phenotype is also widely recog-
nized and includes an absence of either of the major
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Figure 1. Features of ACC-TTLD and Segregation of ARHGAP31 Mutations
(A) Characteristic phenotype of ACC-TTLD showing severe ACC (left panels) and a range of TTLD defects of the hands (middle panels)
and feet (right panels), including partial absence of the fingers and toes and short distal phalanxes of fingers and toes.
(B) Pedigree structure of family AOS-12 showing segregation of the c.2047C>T nonsensemutation represented in the adjacent sequence
chromatogram.
(C) Segregation and sequence chromatogram of the c.3260delA frameshift mutation in family AOS-5. Mutation carriers are denoted
by þ/–.
Key to symbols: square, male; circle, female; upper left shading, aplasia cutis congenita; lower left shading, bony defect/abnormal fonta-
nelle; upper right shading, terminal transverse limb defects; lower right shading, syndactyly; center shading, unsymptomatic mutation
carrier; blank, unaffected.of the disease allele. Clinically, in cases with a known
family history, the presence of either ACC or TTLD has
been considered sufficient to warrant the diagnosis of
AOS.3The AmeWe have now used genome-wide linkage analysis to
study two kindreds with autosomal-dominant ACC-TTLD
and subsequently identified heterozygous mutations in
a RhoGAP family member, Rho GTPase-activating proteinrican Journal of Human Genetics 88, 574–585, May 13, 2011 575
31 (ARHGAP31; MIM 610911), also known as Cdc42
GTPase-activating protein (CdGAP),4 by candidate gene
and exome sequencing. We determined the distribution
of expression ofArhgap31 during development and verified
the pathogenic effect of these mutations in primary
human dermal fibroblasts from patients with ACC-TTLD.
This genetic finding identifies the importance of Cdc42/
Rac1 pathways in the developmental processes of scalp
and limb formation.Subjects and Methods
Clinical Ascertainment
Index subjects were recruited via the Adams-Oliver Syndrome
Support Group, Deeside, UK, and through specialist clinical
genetics centers from within the UK and continental Europe.
Additional family members, including unaffected individuals
and spouses, were then invited to participate in the study. All
participants underwent a detailed physical examination by experi-
enced clinical geneticists. A diagnosis of ACC-TTLD was based on
clinical guidelines3 and supported by radiological investigations in
selected patients. Kindreds AOS-5 and AOS-12 were previously
reported in the medical literature5,6 and were re-examined in
2009.3 All subjects gave written informed consent in accordance
with the protocol approved by the Guy’s and St Thomas’ NHS
Foundation Trust local research ethics committee.
Genotyping, Linkage Analysis, and Mutation
Detection
We extracted genomic DNA from peripheral venous blood by
standard techniques or from saliva by using the Oragene DNA
Self-Collection Kit (DNA Genotek). A genome-wide screen was
performed for 22 individuals from two multigenerational families
via the GoldenGate HumanLinkage V Panel on an iScan System
(Illumina) according to the manufacturer’s guidelines. Linkage
analysis was performedwithMerlin v1.1.2 software under an auto-
somal-dominant disease model with a disease allele frequency of
0.0001 and a penetrance value of 85%. Additional polymorphic
markers for refinement mapping were selected with an average
heterozygosity of 74%. Fluorescently tagged PCR fragments were
analyzed on an ABI3730xl DNA analyzer, and genotypes were
assigned via GeneMapper v3.7 software (Applied Biosystems).
All coding exons and intron-exon boundaries of the candidate
genes ARHGAP31, GSK3B (MIM 605004), LSAMP (MIM 603241),
and POPDC2 (MIM 605823) were screened by direct DNA sequenc-
ing. Primers were designed with Primer3 software.7 PCR products
were purified with ExoSAP-IT (GE Healthcare) and sequenced
with BigDye Terminator v3.1 chemistry (Applied Biosystems).
Sequence traces were aligned to reference with Sequencher v4.9
software (Gene Codes Corporation).
Exome capture of subject III:2 (Figure 1B) was undertaken with
the SureSelect Target Enrichment System (Agilent) and sequenced
on a Genome Analyzer IIx (Illumina). Paired-end sequence reads
were aligned to the reference genome (hg18) with Novoalign soft-
ware (Novocraft Technologies). Duplicate reads, resulting from
PCR clonality or optical duplicates and reads mapping to multiple
locations were excluded from downstream analysis. Single nucle-
otide substitutions and small insertion deletions were identified
and quality filtered with the SamTools software package8 and
in-house software tools.9 Variants were annotated with respect576 The American Journal of Human Genetics 88, 574–585, May 13,to genes and transcripts with the SNPClassifier tool.10 Filtering
of variants for novelty was performed by comparison to dbSNP131
and 1000 Genomes pilot SNP calls (March 2010). The accession
numbers of the reference sequences used for mutation nomencla-
ture are NM_020754.2 (mRNA) and NP_065805.2 (protein).Gene-Expression Analysis
Fetal expression of ARHGAP31 was assessed with a human fetal
multiple tissue cDNA (MTC) panel (Clontech). We performed
PCR with standard protocols and used primers ARHGAP31_3Fw
(50 AGCTCATGTGACCTCACCAA30) andARHGAP31_3Rv (50 AGA
CTGGAGCAGGGAAGGAG 30) to generate a 976 bp fragment.
GAPDH primers (Clontech) were used as an internal control.
For RT-PCR, cDNA was generated from 1 mg of RNA extracted
from patient and wild-type (WT) EBV-transformed lymphoblasts
via the Verso cDNA Kit (ABgene). Real-time quantitative PCR
was performed with ARHGAP31 Taqman gene-expression probes
according to the standard protocol on a real-time PCR 7900HT
(Applied Biosystems). GAPDH (Applied Biosystems) was used as
an endogenous control. We calculated relative levels of gene
expression by SDS v2.2 software (Applied Biosystems) by using
the comparative CT method of data analysis (relative quantity ¼
2  DDCt).Whole-Mount In Situ Hybridization
The genomic sequence of Arhgap31 was obtained from Ensembl.
We designed primers by using Primer3 software7 to produce
a PCR product of 543 bp from the 30 UTR of Arhgap31 (genomic
location: chromosome 16:38,599,795–38,600,337). T3 and T7
RNA polymerase sites were added to the 50 end of the forward
and reverse primers respectively (forward: 50 AATTAACCCTCAC
TAAAGGCTGCTGGAGGAAGGTTTCTG 30; reverse: 50 TAATACG
ACTCACTATAGGCGCCTCTCCACACCATATTT 30). Digoxigenin
(DIG)-labeled (Roche Applied Science) antisense riboprobes were
generated by in vitro transcription of purified PCR-amplified
DNA template with T7 RNA polymerase.
CD1 mouse embryos at developmental stages 9.5, 10.5, 11.5,
and 12.5 days postcoitum (dpc) were obtained from the Mary
Lyon Centre, MRC Harwell, Oxfordshire, UK. Embryos were fixed
overnight in 4% paraformaldehyde at 4C, stored in methanol,
and rehydrated in a series of graded methanol washes in PBS
and 0.1% Tween 20 (PBST). Proteinase K (10 mg/ml) (Roche
Applied Science) permeabilization was performed for 15–35 min
depending on the stage of development. Embryos were washed
twice in 0.1 M triethanolamine, and acetic anhydride was added
to the secondwash. Samples were thenwashed in PBSTand refixed
in 4% PFA/0.2% gluteraldehyde for 20min. After washing in PBST,
embryos were prehybridized for 2 hr at 60C and hybridized for
48 hr at 60C in hybridization buffer containing the DIG-labeled
probe. Samples were washed three times for 20 min each time in
23 SSC and Tween 20 and then three times for 30 min each
time in 0.23 SSC and 0.1% Tween 20 at 60C. Samples were
then washed twice for 15 min each time in maleic acid buffer
(MAB) at room temperature. A final wash for 2 hr in MAB, 2%
Boehringer-Mannheim blocking reagent (BMB), and 20% heat-
treated lamb serum solution at room temperature was performed
before overnight incubation in the same solution containing
a 1/2000 dilution of DIG antibody coupled to alkaline phospha-
tase (Roche Applied Science). Embryos were then washed three
times for 1 hr each time in MAB and color detected with 2 ml of
BM purple precipitating solution (Roche Applied Science).2011
Optical Projection Tomography
Whole-mount in situ hybridization (WISH) was performed as
described above. Embryos were mounted in 1% agarose, dehy-
drated in methanol, and then cleared overnight in BABB (1 part
benzyl alcohol: 2 parts benzyl benzoate). We then imaged samples
with a Bioptonics Optical Projection Tomography (OPT) Scanner
3001 by using brightfield to detect the staining and tissue
autofluorescence (excitation 425 nm, emission 475 nm) to capture
the anatomy.11 The resulting images were reconstructed with
Bioptonics proprietary software and automatically thresholded
and merged to a single 3D image output via Bioptonics Viewer
software. The downstream digital dissection and sectioning were
performed with Amira software (Visage Imaging).
Cloning and Mutagenesis
Full-length Myc-tagged ARHGAP31 was generated as previously
described.4 We engineered mutant constructs by performing site-
directed mutagenesis with the QuickChange kit (Stratagene) on
the WT template. Primers are available on request.
Cell Culture
Cells were maintained at 37C in a humidified incubator with 5%
CO2. Human endometrioid cancer (HeLa, ATCC) and human
embryonic kidney (HEK293) cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 4.5 g/ml
GlutaMax and 10% heat-inactivated fetal bovine serum (FBS).
EBV-transformed lymphoblasts (ECACC) from a WT control and
ACC-TTLD patients with and without ARHGAP31 mutations
were cultured in RPMI-1640 supplemented with 10% heat-inacti-
vated FBS. Human primary dermal fibroblast cells were established
from 4 mm tissue biopsies from a WT control individual and an
ACC-TTLD patient carrying the p.Gln683X mutation. Tissues
were enzymatically dissociated with accutase, and fibroblasts
were grown in basal medium 106 supplemented with 2% (v/v)
FBS, 1 mg/ml hydrocortisone, 10 ng/ml human epidermal growth
factor, 3ng/mlbasicfibroblast growth factor, and10mg/mlheparin.
Normal human neonatal dermal fibroblasts (HDF; Lonza), used as
an additional control for proliferation assays, were cultured under
the same conditions as described above. All cell culture reagents
were obtained from Invitrogen. Transient transfections of HeLa
cells were performed with FuGENE (Roche) in accordance with
manufacturer’s instructions and with a 3:1 ratio of transfection
reagent to DNA.
Immunofluorescence
We plated HeLa cells and fibroblasts in 6-well plates (Corning) on
acid-treated glass coverslips (Laboratory Sales Limited) and
allowed them to grow until 80% confluent. Cells were fixed in
ice-cold methanol, rehydrated with 13 PBS, and blocked with
a 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in 13 PBS
solution. After blocking, we incubated cells with a polyclonal
rabbit antibody raised against a peptide corresponding to amino
acids 541–562 of mouse Arhgap31 (PRD1) and purified them on
a protein A-sepharose column (1:500 dilution). After washing
with blocking solution, a secondary rabbit-specific fluorophore-
tagged antibody (Abcam) was added for 1 hr. Coverslips were
rinsed and mounted on slides with hard-set mounting medium
containing a DAPI nuclear stain (Vector Labs). Golgi and cytoskel-
eton visualizations were performed with 58K Golgi protein and
monoclonal tubulin antibodies (Abcam), respectively. Antibodies
were diluted according to manufacturer’s instructions. PRD1 anti-The Amebody specificity tests were performed with a preimmune serum
from the antibody host rabbit in place of the Arhgap31 antibody.
A second specificity test utilized a blocking peptide specific to the
PRD1 antibody epitope used at a 10:1 concentration (peptide to
antibody). We further used a blocking peptide specific to a random
region of Arhgap31 as an additional negative control. Both block-
ing peptides were synthesized by Sigma-Aldrich. All images were
acquired on a Zeiss LSM 510 confocal microscope and processed
with Adobe Photoshop. Statistical comparisons for cell rounding
experiments were conducted via a Fisher’s exact test.G-LISA Cdc42 Activation Assay
HEK293 cells were grown to 70% confluency on 100 mm dishes
and transiently transfected with polyethyleneimine (Polysciences)
and 100 ng of empty vector DNA or vector-encoding Myc-tagged
WTARHGAP31, p.Lys1087SerfsX4, or p.Gln683X. Cells were lysed
16 hr after transfection according to manufacturer’s instructions
(Cytoskeleton) and snap-frozen in liquid nitrogen. Levels of tagged
proteins and Cdc42 were determined by immunoblotting with
polyclonal Myc-specific (Cell Signaling Technology) and Cdc42-
specific (Santa Cruz Biotechnology) antibodies, respectively. The
relative amounts of GTP-bound Cdc42 in each condition were
determined in duplicate. For each Cdc42-GTP measurement,
100 mg of protein lysate was used. To compare WT and mutant
ARHGAP31 activity, we used a Student’s t test with a two-tail
distribution.Immunoprecipitation
HEK293 cells were cotransfected with mouse pRK5Myc-Arhgap31
(1083–1425) and pEGFP-Arhgap31 (1–221 or 1–820). After 16 hr,
cells were lysed on ice in 25 mM HEPES (pH 7.4), 100 mM NaCl,
10 mM MgCl2, 5% glycerol, 1% NP-40, 1 mM Na3VO4, 10 mM
NaF, 1 mM PMSF, and protease cocktail inhibitors (Roche Applied
Science). Protein lysates were centrifuged for 10 min at 14,000 g
and precleared for 1 hr at 4C with protein G-sepharose (GE
Healthcare). Supernatants were incubated for 3 hr at 4C with
2 mg of monoclonal Myc-specific antibody (9E10) and protein G-
sepharose. Immune complexes were washed three times in lysis
buffer and resuspended in SDS sample buffer. Proteins were
resolved by SDS-PAGE and detected by immunoblotting with anti-
bodies to GFP (A6455, Molecular Probes) and Myc.Proliferation Assay
The CyQUANT fluorescence-based microplate assay was used for
quantitation of cell number. To generate a standard calibration
curve, we measured binding to cellular nucleic acids by using
485 nm (510 nm) excitation and 530 nm (512.5 nm) emission
filters with a CytoFluor 2350 fluorescence microplate reader.
The fluorescence emission of the dye-nucleic acid complexes
was then correlated linearly with cell numbers from a dilution
series ranging from 100 to 50 3 104 cells, measured with a hemo-
cytometer.
Sample cells were lysed at room temperature with 1 ml of
CyQUANT GR dye with lysis buffer and incubated in darkness
for 2–5 min at room temperature. Six-well culture plates of cells
were harvested on days 1–9 and lysed with 200 ml of CyQUANT
GR dye with lysis buffer. Sample fluorescence was measured,
and growth curves were plotted as cell number over time in
culture. For each independent control (WT and HDF), we used
an unpaired t test to compare cultured cell numbers with the
patient (p.Gln683X) sample at each time point.rican Journal of Human Genetics 88, 574–585, May 13, 2011 577
Wound-Healing Assay
Wound-healing assays were performed with WT and p.Gln683X
primary dermal fibroblast cells plated on fibronectin-coated
35 mm tissue culture dishes with an IBIDI chamber at a density
of 8500 cells/well. Cells were serum- and growth-supplement-
starved for 12 hr before removing the cells from half of each
well with a sterile rubber policeman. Wounding was performed
after a 12 hr incubation, cultures were washed twice with 13
PBS, and wound margins were photographed (t ¼ 0 hr). The
same wound margin fields were photographed at different time
points, pictures were superimposed, and areas were measured
with ImageJ software.Results
Genome-wide Mapping and Identification
of ARHGAP31 Mutations
Linkage analysis identified a locus for ACC-TTLD at
3q13.31-q13.33 on chromosome 3 (Figure S1). Subsequent
refinement mapping defined a 5.53 Mb critical interval
flanked by markers rs714697 and D3S4523 and containing
a total of 21 protein-coding genes and three open-reading
frames (Figure S2). We sequenced four genes in affected
members of the linked AOS-5 and AOS-12 families. In
each kindred we identified within the terminal coding
exon of ARHGAP31 a distinct sequence variant
(c.2047C>T and c.3260delA) that segregates with the
syndrome phenotype and predicts the formation of prema-
ture truncating mutations (p.Gln683X and p.Lys1087-
SerfsX4) (Figures 1B and 1C). No likely disease-causing
sequence variants were detected in the other genes
analyzed. To comprehensively exclude the existence of
a pathogenic mutation in the linked interval, we per-
formed whole-exome sequencing in one individual from
family AOS-12 and verified the c.2047C>T ARHGAP31
nonsense mutation as the only novel variant within the
extended 13.2 Mb linkage region (Figure S2).
We screened ARHGAP31 by DNA sequencing in affected
members from three other multiplex kindreds that are
unlinked to the chromosome 3 locus and from a cohort of
43 sporadic individuals with features of ACC and TTLD,
either alone or in combination. A nonsynonymous poly-
morphism (c.2180C>T, p.Thr727Ile) was detected in two
sporadic cases, but no pathogenic sequence variants were
identified in this extended cohort. To exclude the possi-
bility that the truncating variantswere also polymorphisms
or that ARHGAP31 harbors frequent but functionally insig-
nificant variation, we resequenced all 12 exons in 72 unre-
lated control individuals. None of these individuals carried
either of the likely disease-causingARHGAP31mutations or
any other missense or splice-site variants. We additionally
sequenced exon 12, the site of the putative disease-causing
mutations, in a further 1138 unrelated control subjects of
European origin. Although the c.2180C>T polymorphism
was detected in two control subjects, neither of the ACC-
TTLD truncating mutations was detected in the combined
total of over 2000 chromosomes assayed.578 The American Journal of Human Genetics 88, 574–585, May 13,ARHGAP31 Expression during Early Development
Analysis of ARHGAP31 transcript expression showed abun-
dant and ubiquitous levels in all human fetal tissues exam-
ined (Figure S3). To determine the regional expression of
Arhgap31 mRNA, we studied mouse embryos during early
development (Figure 2). At 9.5 dpc, the strongest expres-
sion is in the developing heart, with regional localization
to the ventral walls of primitive ventricle and primitive
atrium (Figures 2A and 2B). By 10.5 dpc, Arhgap31 expres-
sion becomes largely restricted to the lateral walls of
the developing ventricle, and expression in the primitive
atrium becomes localized to its outer wall (Figures 2C
and 2D). At 11.5 dpc, Arhgap31 expression is largely
restricted to the surface ectoderm, and strong expression
overlies the entire heart field, symmetrical regions of the
head and flank, and the apical regions of the hand and
foot plates (Figures 2E and 2F). By 12.5 dpc, the expression
in the surface ectoderm is not detectable by WISH (data
not shown).
Effect of ARHGAP31 Mutations
To determine the impact of exon 12 premature termina-
tion mutations (Figure 3A), we assessed transcript stability
by quantitative RT-PCR of RNA extracted from lympho-
blasts. A comparison between WT control and two related
subjects, both heterozygous for the c.2047C>T mutation,
showed no reduction in the abundance of ARHGAP31
transcript, in support of the hypothesis that the mutant
transcript is not removed by the process of nonsense-medi-
ated decay (Figure 3B).
Because the antibody to ARHGAP31 was unsuitable
for protein detection by immunoblot analysis, we used
immunofluorescence and found ARHGAP31 predomi-
nantly localized to the Golgi. We found no indication of
protein degradation, such as loss of staining intensity or
aggregate formation, andARHGAP31 localization appeared
normal in ACC-TTLD primary fibroblasts that harbor the
p.Gln683X mutant protein (Figure 3C). However, subtle
differences in localization or indeed organellemorphology,
although not qualitatively evident, cannot be excluded.
ARHGAP31 is amemberof theRhoGAP familyofproteins
known to inactivate the Rho GTPases Cdc42 and Rac1.4
Thus, we next investigated the impact of truncation of
ARHGAP31 on GAP activity. We performed in vitro experi-
ments in HEK293 cells and found that, relative to full-
length ARHGAP31, both truncated proteins displayed
amarked augmentationofGAP activity uponCdc42, result-
ing in a significant downregulation of the active GTPase
(Figure 4A). We conclude that both disease mutations in
ARHGAP31 behave as dominant gain-of-function alleles.
The ARHGAP31 mutations associated with the ACC-
TTLD phenotype result in the removal of the C-terminal
tail. To test the possibility that the C terminus of
ARHGAP31 affects the GAP activity through intramolecu-
lar interactions, we generated green fluorescent protein
(GFP)-tagged ARHGAP31 deletion constructs to perform
protein immunoprecipitation studies in HEK293 cells2011
Figure 2. Expression of Arhgap31 during Mouse Embryogenesis
(A) Right lateral view of volume rendered OPT 3D representation of a 9.5 dpc mouse embryo showing Arhgap31 expression (in red) in
developing heart (he).
(B) Digital section of same embryo as in (A) showing expression in ventral wall of the early ventricle and atrium of the heart and the first
pharyngeal arch (pa).
(C) Frontal view of rendered and (D) digital coronal section of 10.5 dpc mouse embryo with expression in the lateral walls of the early
ventricles of the heart and the first-pharyngeal-arch-derived facial mesenchyme (fm).
(E and F) By 11.5 dpc the expression of Arhgap31 is restricted to distinct regions of the surface ectoderm (se), including the upper and
lower limb bud (lbe).with a Myc-tagged construct encoding the C terminus.
Indeed, we found that the C terminus of ARHGAP31 is
able to interact with the N-terminal region (amino acids
1–820), and we further refined the interaction to a region
comprising the RhoGAP domain (amino acids 1–221).
Although our data do not exclude the possibility that the
C terminus might also bind a second motif downstream
of the RhoGAP domain, these results indicate the potential
for an autoregulation mechanism (Figure 4B).
In Vitro Phenotypic Analysis of Mutant ARHGAP31
Perturbation of Cdc42 and/or Rac1 signaling pathways
impacts directly upon cell proliferation and migration in
a cell-specific manner.12,13 Therefore, we hypothesized
that the ACC-TTLD defects would have an impact upon
cell proliferation and ordered cell migration. Following
p.Gln683X fibroblasts over a 9 day period revealed a signif-
icantly reduced rate of cell proliferation (Figure 5A). In
addition, we performed wound-healing assays with theThe Amemutant fibroblasts, which showed significant differences
in cell migration, suggestive of altered cell motility (Figures
5B and 5C). The rounding of cells is a characteristic of
impairment of the ordered process of actin polymerization
and associated to a specific mode of cell movement during
tumor cell migration.13 Transient transfection of disease-
causing ARHGAP31 constructs induced a rounded pheno-
type in a significant proportion of HeLa cells, in keeping
with recent observations of suppressed Cdc42 activity
(Figures 5D and 5E).14 However, cytoskeletal organization,
as assessed by F-actin staining of human fibroblasts hetero-
zygous for the p.Gln683X mutation, was not qualitatively
distinct from controls, presumably because of dosage
compensation by the WT allele (data not shown).
Discussion
Fundamental insight into the signaling pathways that are
necessary for normal limb patterning and outgrowth hasrican Journal of Human Genetics 88, 574–585, May 13, 2011 579
Figure 3. Transcript and Protein Expres-
sion in WT and Mutant Cells
(A) Schematic of the ARHGAP31 structure
showing the position of the mutations
identified in exon 12. The ARHGAP31
structure beneath depicts the known
RhoGAP and proline-rich domains, a site
of phosphorylation by GSK-3.
(B) Real-time quantitative RT-PCR is used
for the examination of ARHGAP31 tran-
script levels in lymphoblasts from two
related subjects heterozygous for the
c.2047C>T nonsense mutation as com-
pared to a genotypically normal control
(WT). Patient and control samples show
no appreciable difference in transcript
expression. Sample identifiers refer to
the pedigree structure in Figure 1B. The
ACC-TTLD control is a patient with no
ARHGAP31 mutation (molecular genetic
basis unknown). Data represent mean 5
standard deviation (SD) from three inde-
pendent experiments. RQ is used as an
abbreviation for relative quantification.
(C) Immunostaining of (i) endogenous
ARHGAP31 (red) and (ii) Golgi (green);
marked levels of colocalization to the
Golgi apparatus in HeLa cells are visible
(iii). The nucleus is stained in blue. (iv)
The high specificity of the ARHGAP31
antibody is indicated by the absence of
staining in the presence of blocking
peptide to the binding epitope. In both
(v) WT and (vi) mutant (p.Gln683X) fibro-
blasts, ARHGAP31 (green) localizes to the
Golgi (red) and appears identical and of
equivalent intensity. Images in the inset
boxes show a 33 magnification of the
single cells marked by the dashed lines.been gained primarily from the study of model organisms
and inherited disorders of limb formation.15,16 The fibro-
blast growth factor (FGF), bone morphogenetic protein
(BMP), hedgehog, and Wnt protein families have all
been implicated in this important paradigm of organogen-
esis. Spatial and temporal expression of these signaling
molecules is critical. For example, in the apical ectodermal
ridge (AER), a specialized epithelium located along the
distal tip of the limb bud, molecular signals generated
by several members of the Fgf family control limb
outgrowth and proximal-distal patterning.17 Wnt signals
interact with FGFs in the AER to maintain mesenchymal
progenitors in an undifferentiated, proliferative state.18
By contrast, the expression of BMP ligands regulates
dorsal-ventral patterning and interdigital cell death19 and
inhibits sonic hedgehog transcription through disruption
of FGF and Wnt signaling.20 Further delineating the
crosstalk and interaction between such genes and path-
ways is required for an integrative model of limb organo-
genesis; however, additional critical steps remain to be
elucidated.15580 The American Journal of Human Genetics 88, 574–585, May 13,In this study, we have used a classical positional cloning
approach in conjunction with the contemporary tech-
nology of exome sequencing21 to identify distinct trun-
cating mutations within the terminal exon of ARHGAP31.
Combining candidate gene analysis with large-scale exome
sequencing now provides an opportunity for rapid detec-
tion of genes in Mendelian disease. Importantly, we have
shown that this strategy can be successful with exome
data from a single affected individual and have been able
to verify truncating mutations of ARHGAP31 as the only
novel variation within our extended linkage interval.
The clinical phenotypes in the two kindreds with
ARHGAP31 mutations share a number of features. Both
mutations are associated with scalp aplasia cutis congenita
and upper and/or lower limb defects of significant vari-
ability and reduced penetrance, including short distal
phalanges, partial absence of the fingers and toes, and
cutaneous syndactyly of toes 2 and 3 (Figures 1B and
1C). Using whole-mount in situ hybridization and optical
projection tomography in mouse embryos, we have
detected Arhgap31 transcript expression in distinct regions2011
Figure 4. Analysis of GAP Activity in ARHGAP31 Truncations
(A) G-LISA assays measuring the relative amounts of Cdc42-GTP
levels in HEK293 cells expressing Myc-tagged WT ARHGAP31
(full-length), p.Lys1087SerfsX4 or p.Gln683X. Relative Cdc42-
GTP values are expressed as a ratio of Cdc42-GTP levels found in
full-length ARHGAP31. Data are presented as mean 5 SEM from
four independent experiments. E.V. ¼ empty vector; **p <
0.0002, ***p < 0.00001.
(B) Immunoprecipitation of mouse ARHGAP31 deletion con-
structs were used to map the intramolecular interaction between
C-terminal amino acids 1083-1425 and the proximal 221 residues
harboring the RhoGAP domain. Full-length protein products are
marked by the arrows (smaller bands represent degradation prod-
ucts; the asterisk [*] indicates the IgG light chain). Levels of trans-
fected proteins, assessed by immunoblotting of the lysates with
Myc antibody, are displayed in the lower panel.of the surface ectoderm, including the head and upper and
lower limb buds, at 11.5 dpc. Expression in the distal tip of
the limb buds during late stages of embryonic develop-
ment would be consistent with a role in limb outgrowth
and proximal-distal patterning. Interestingly, and despite
evident expression of Arhgap31 in the developing mouse
heart, no affected subjects displayed evidence of congen-
ital cardiac abnormalities, which is a widely recognized
feature of the ACC-TTLD spectrum. To address this further,
we screened ARHGAP31 in an extended panel of ACC-
TTLD patients with and without cardiac abnormalities.
No additional mutations were identified, indicating that
defects in ARHGAP31 account for only a small proportionThe Ameof subjects with the ACC-TTLD spectrum of clinical
features. Future studies will probably identify additional
gene defects causative of AOS.
Our data suggest the c.2047C>T nonsense mutation
does not activate the nonsense-mediated decay pathway,
in keeping with premature termination codons down-
stream of the final splice junction.22 Immunofluorescence
studies identified the expression and localization of
mutant protein to be confined to the Golgi apparatus,
a site of activity of Cdc42, at levels comparable to those
observed for WT ARHGAP31.23 The Rho family members
Cdc42 and Rac1 are active when GTP bound. The hydro-
lysis of GTP, for example by ARHGAP31, leads to inactiva-
tion of Cdc42 and Rac1 and, as such, intracellular Cdc42-
and Rac1-GTP levels are inversely proportional to the
activity of ARHGAP31. Measurements of GAP activity, as
determined by G-LISA assays, demonstrated that both
truncating mutations result in a significant downregula-
tion of active Cdc42, compatible with a dominant gain-
of-function mechanism of these disease-causing alleles.
Both the ARHGAP31 mutations associated with the
ACC-TTLD phenotype are predicted to truncate the
C-terminal tail. We postulated that the C terminus of
ARHGAP31 is capable of interacting with the amino
terminus so as to shield the RhoGAP domain, consistent
with comparable autoregulatory mechanisms reported
for other members of GTPase pathways, for example
p50RhoGAP, N-chimaerin, and the downstream signaling
effectors WASP and PAK1.24–27 In this study, we demon-
strate an interaction between the C terminus of ARHGAP31
and the N-terminal RhoGAP domain, suggesting a model
in which truncation of the ARHGAP31 C-terminal domain
inmutant proteins would result in the exposure of a consti-
tutively active RhoGAP catalytic site (Figure 6A).
Perturbation of Cdc42 and/or Rac1 signaling impacts
upon directed migration, proliferation, and differentiation
in a cell-specific manner.12 Constitutive inactivation of
Cdc42 by GTPase inhibitors, for example VopS, leads to
cell rounding because of disruption of the actin cytoskel-
eton.14 Furthermore, low Rac1 activity is associated
with a rounded mode of cell movement.28 In this report,
we demonstrate a very similar outcome for cell mor-
phology upon transient overexpression of ARHGAP31
mutant proteins and a significant disruption of cell migra-
tion in fibroblast mutant cells, pointing toward the unreg-
ulated suppression of Cdc42/Rac1 function. Importantly,
ARHGAP31 has recently emerged as a regulator of Cdc42
and Rac1 signaling to the cytoskeleton and thereby plays
a key role in controlling the temporal and spatial cytoskel-
etal remodeling necessary for the precise control of cell
morphology and migration.29 In addition, its GAP activity
is regulated in an adhesion-dependent manner and
appears to be required for normal cell spreading, polarized
lamellipodia formation, and cell migration.29 Although
the wound-healing assays performed in this study do not
measure the direction of cell movement, it is feasible
that the increased GAP activity in ARHGAP31 mutantrican Journal of Human Genetics 88, 574–585, May 13, 2011 581
Figure 5. Functional Characterization of ARHGAP31 Mutations
(A) Bar chart comparing the proliferative activity of p.Gln683X primary dermal fibroblasts (light gray bars) with two distinct control
fibroblast cell lines (black and dark gray bars). Data represent mean 5 SEM for three independent experiments. Statistical analysis of
each time point (days 1–9) revealed a significant decrease in the proliferative ability of cells carrying the p.Gln683X mutation when
compared independently to each of the two unaffected controls (*p < 0.01). The abbreviation WT indicates primary dermal fibroblasts
from a tissue biopsy; HDF is used as an abbreviation for human dermal neonatal fibroblasts.
(B) Wound-healing migration assay showing coverage of a cell-free gap by primary dermal fibroblasts heterozygous for the p.Gln683X
mutation and WT control fibroblasts at 24 hr after wounding.
(C) Plot showing percentage of wound restoration at 18, 24, and 30 hr after wounding. Fibroblasts heterozygous for the p.Gln683X
mutation (light gray bars) migrate at a significantly faster rate than similar WT control fibroblasts (black bars). Data show mean 5
SEM from three independent experiments.
(D) HeLa cells transiently transfected with Myc-tagged WT ARHGAP31, p.Gln683X, and p.Lys1087SerfsX4 constructs. Cell shape was
visualized by confocal microscopy for tubulin (red) and transfected cells identified by costaining with fluorescent conjugated Myc anti-
body (green). DAPI was used to stain the cell nuclei (blue). Rounded cells are indicated by the white arrows and 23 highermagnifications
of individual cells are shown above.
(E) Bar chart showing themean percentage of rounded HeLa cells observed for each ARHGAP31 construct from three independent trans-
fection experiments (error bars denote SD).
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Figure 6. Schematic of Disrupted
ARHGAP31 Signaling
(A) Schematic representing the putative
mechanism of disease. The C terminus of
ARHGAP31 inhibits the activity of the
RhoGAP domain by specific interaction
with amino acids 1–221 (red ‘‘X’’). Trun-
cated mutant proteins lacking the C
terminus would therefore be incapable of
autoinhibition, and this would result in
a constitutively active RhoGAP domain.
(B) Schematic of the normal ARHGAP31
signaling system. ARHGAP31 cycles Cdc42
from an active to an inactive form by
hydrolysis of GTP to GDP. GSK-3b upregu-
lates ARHGAP31 levels, probably through
phosphorylation at a consensus ERK1 site.
Activated Cdc42 promotes actin polymeri-
zation and cellular processes, including
migration, and acts to inhibit GSK-3b
activity by stimulating PKCz phosphory-
lation of GSK-3b. Wnt signaling is an
additional negative regulator of GSK-3b
activity. Downregulation of GSK-3b leads
to decreased proteasomal degradation of
cytosolic b-catenin. Active b-catenin trans-
locates to the nucleus, whereupon the
engagement of transcriptional cofactors
controls the differentiation of progenitor
cells in the skin.
(C) In ACC-TTLDmutant cells, constitutive activation of ARHGAP31 leads to an imbalance between active and inactiveCdc42. A decrease
in the levels of active GTP-bound Cdc42 results in reduced activation of PKCzwith a concomitant increase in b-catenin degradation and
disruption of cellular processes.
The following abbreviations are used: PKCz, protein kinase C; GSK-3b, glycogen synthase kinase 3 beta; Pi, inorganic phosphate.fibroblasts leads to a loss of adhesion and/or structural
defects in cell protrusion formation, regulated by Cdc42
and Rac1,30 thus resulting in disorganized cell migration.
A more comprehensive disease-cell-based study aimed in
particular at examining cytoskeletal dysfunction is now
required to build on these early observations and further
define the mechanisms driving pathogenesis in this
disorder.
Further insight into the wider ARHGAP31 signaling
pathway is provided by a keratinocyte-specific Cdc42
knockout mouse model, which offers an integrated model
for the molecular basis of the AOS phenotype.31 Mutant
mice display cellular abnormalities of skin morphogenesis,
phenotypically illustrated by progressive loss of hair folli-
cles. Central to this process is the stabilization of b-catenin
by Wnt and Cdc42 signaling, which together inhibit the
activity of glycogen synthase kinase 3 beta (GSK-3b), a
critical driver of b-catenin degradation.32 By contrast,
ARHGAP31 levels are augmented by GSK-3b activity.33
We would suggest that in ACC-TTLD cells the inactivation
of Cdc42 by constitutively active mutant ARHGAP31
would compromise this critical negative feedback loop
and result in upregulation of mutant ARHGAP31 by GSK-
3b and concomitant destabilization of b-catenin with
consequent impairment of cellular processes, in particular
progenitor cell differentiation, requisite for skin layer and
hair follicle production (Figures 6B and 6C). In addition
to this, Rac1 activity has recently been implicated inThe Amenuclear localization of b-catenin during canonical Wnt
signaling,34 and keratinocyte-restricted deletion has been
identified as having a critical role in hair follicle integ-
rity.35 More importantly, genetic removal of Rac1 in the
mouse embryonic limb bud ectoderm disrupts Wnt
signaling and results in severe truncations of the limb.
Furthermore, conditional deletion of Rac1 in the mouse
limb bud mesenchyme also leads to skeletal deformities,
including abnormal fusion of the skull, developmental
limb defects, and syndactyly.36 These reports, combined
with our ARHGAP31 study, demonstrate the crucial roles
of Cdc42 and Rac1 in skin morphogenesis and limb devel-
opment. Clearly, additional work, informed by our genetic
findings, will now be required to further elucidate these
early mechanistic insights and confirm the molecular
processes proposed within this model.
Taken together, our findings demonstrate that heterozy-
gous gain-of-function mutations in ARHGAP31 cause an
autosomal-dominant form of ACC-TTLD through intro-
duction of premature termination codons in the terminal
exon of the gene. Expression of Arhgap31 during develop-
ment appears confined to the limb buds, cranium, and
early cardiac structures and provide a remarkable correla-
tion with the developmental defects that define ACC-
TTLD. This report generates insight into the critical path-
ways regulating the processes of cell proliferation and
movement in vivo, and the consequences for human
health with dysregulation of skin and limb formation.rican Journal of Human Genetics 88, 574–585, May 13, 2011 583
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